Company Performance Metrics
Oxymo Technologies develops biotechnology-based antiviral therapeutics targeting Herpes Simplex Virus infections. The company focuses on controlled oxidative biology, using a peroxomolybdate-based antiviral platform that generates specific reactive oxygen species to inactivate HSV inside and outside cells. Its lead asset, Oximo, is a topical drug
candidate designed to treat recurrent oral and genital herpes by blocking viral entry, disrupting viral particles, and halting replication throughout the infection cycle. Oximo is intended for early intervention during recurrent herpes episodes to help prevent lesion formation and support natural skin recovery. Oxymo Technologies advances its candidates through discovery, preclinical evaluation, and regulatory preparation toward clinical trials in infectious disease and antiviral therapy.
